Browse Articles
Discover research articles across all indexed journals
Late-Stage Carboranylation of Nucleos(t)ides Enabled by Minisci and Pd-Catalyzed B–N Cross-Coupling Reactions: Toward the Synthesis of Carboranyl-Modified Oligonucleotides
Bio-efficacy of Syzygium aromaticum bud extract as eco-friendly green acaricide for controlling Hyalomma dromedarii
Abstract The most common hard tick in Egypt is Hyalomma dromedarii as a one of the most dangerous ectoparasites. The current study aims to detect the chemical composition of Syzygium aromaticum bud ethanolic extract using GC-MS and some phytochemical analysis in addition to investigating its acaricidal activity on H . dromedarii engorged females through biological and biochemical studies. The GC-MS revealed the presence of eugenol, eugenol acetate and D-(-)-fructofuranose as the most active compounds, and it appeared to be rich in alkaloids, flavonoids, phenolic compounds, tannins and terpenoids. At high concentration, the extract caused mortality to reach 100% after 35 days of treatment in engorged females, with LC 50 reached 100.22 and 0.83 mg/mL after the 3rd and 5th week (half and end of examined period) following treatment, respectively. The blood digestion was affected by significantly decreasing in their body weights. Furthermore, the extract showed a decrease in their oviposition, hatchability, and fertility. The extract at 100 mg/mL caused a reduction in ovary total protein content with disappearance of some protein bands using SDS-PAGE, compared with the control group. Overall, the current study revealed the effectiveness of S . aromaticum extract as a bio-acaricide for controlling H . dromedarii and it recommended numerous additional field studies to assess its effectiveness under different conditions.
Incretin-based multi-agonist reverses obesity and diabetes
Transformative Powder Fibration toward Hierarchical Ceramic Aerogels for Multifunctional Aerospace Systems
ABSTRACT Extreme aerospace environments demand ultralight materials capable of simultaneously withstanding rapid thermal fluctuations, intense mechanical shocks, and strong electromagnetic radiation. However, integrating thermal stability, mechanical resilience, and multifunctionality within a single ceramic aerogel remains challenging due to the intrinsic brittleness and structural instability of conventional systems. Here, we report a scalable powder‐to‐fiber transformation strategy to construct hierarchical ceramic aerogels reinforced with cellulose‐derived topological microscrolls. This process converts particle‐based networks into entangled fibrous frameworks, enabling cooperative deformation and structural robustness. As a result, the aerogels exhibit near‐temperature‐invariant superelasticity (up to 95% strain recovery), negative thermal expansion, and ultralow thermal conductivity (3.6 mW m − 1 K − 1 in vacuum). They maintain structural integrity under extreme conditions, including direct flame exposure and rapid thermal cycling from −196°C to 1300°C, while delivering high electromagnetic interference shielding effectiveness (above 56 dB across 8.2–40 GHz). These integrated properties establish a robust strategy for designing multifunctional ceramic aerogels for aerospace structures, thermal protection, and other extreme‐environment applications.
Interference Crystallization Rebalances Facet Competition for Efficient and Stable Perovskite Solar Cells
ABSTRACT Crystallographic orientation governs lattice strain, defect formation, and stability in perovskite solar cells, yet precise control remains challenging in sequential deposition due to the intrinsic growth dominance of low‐surface‐energy (100) facets. Here, we report an interference crystallization strategy that reshapes facet competition by modulating A‐site intercalation kinetics. Incorporation of a sulfonate‐based additive into the PbI 2 precursor imposes facet‐dependent kinetic perturbation during FA + insertion. Preferential adsorption of this additive on the (100) surface restricts A‐site accessibility and selectively retards its growth, whereas weaker interaction with the (111) surface preserves intercalation kinetics and enables its competitive development. This asymmetric interference establishes a balanced (100)/(111) orientation distribution, alleviating residual lattice strain associated with single‐facet dominance. The coexistence of both facets integrates their complementary merits, combining the superior optoelectronic quality of (100) with the enhanced moisture tolerance of (111). Meanwhile, strong surface adsorption of this additive on both facets provides additional defect passivation, suppressing non‐radiative recombination. Devices fabricated via this strategy achieve a power conversion efficiency of 26.41% and exhibit negligible degradation after 1300 h maximum power point tracking, demonstrating interference‐mediated crystallization as a viable pathway for orientation regulation in sequentially deposited perovskites.
Global identification of Chromobacterium violaceum T6SS effectors reveals an Rhs antibacterial toxin featuring FIX and ADP-ribosyltransferase domains
Phase 1 dose escalation of ACM-CpG, a polymersome-delivered TLR9 agonist for advanced solid tumors after prior treatment with checkpoint inhibitor.
TPS91 Background: ACM-CpG is a novel innate immune activator comprising of TLR9 agonist CpG7909 encapsulated within polymer vesicles (“polymersomes”). This formulation enhances in vivo immune activation compared with free CpG. ACM CpG is preferentially taken up by the myeloid compartment leading to myeloid specific and myeloid driven immune activation. In preclinical animal models, ACM-CpG induced tumor regression, durable antitumor immune memory, and growth inhibition of distal, non-injected tumors. Intramuscular administration also achieved tumor control on abscopal subcutaneous tumors. Based on these findings, a Phase I clinical trial (NCT06587295) was initiated at the National Cancer Centre Singapore to evaluate the safety and early efficacy signals of intramuscular ACM-CpG monotherapy in patients with advanced solid malignancies. Methods: This is a 3+3 dose-escalation study of ACM-CpG administered intramuscularly as monotherapy, weekly over the first 8 weeks then fortnightly from the 9th week onwards. Eligible patients had advanced cancers with prior clinical response to immune checkpoint inhibitors, either alone or in combination with chemotherapy with clinical progression of disease prior to enrolment on trial. Dose escalation was performed over 3 dose levels. Safety and clinical review was performed prior to each dosing. Scans were performed 4-weekly in the first 8 weeks then 8-weekly thereafter. Serial cellular and soluble changes of immune response in peripheral blood were profiled using mass CyTOF, multiplex cytokine assays (Luminex/Olink), IFN-γ ELISPOT, and single-cell RNA/TCR sequencing. Clinical trial information: NCT06587295 .
Expectations and unmet needs of cancer patients seeking Ayurved Rasayana therapy: A cross-sectional study from India.
346 Background: The objective of this study was to assess the expectations and objectives of cancer patients opting for Indian system of medicine-Ayurveda, and to find out their unmet medical needs so as to facilitate better patient education and evidence-based integration. Methods: This study was done at our super speciality Ayurveda cancer clinic in India. In this cross-sectional study done between 2020 to 2025 a total of 3351 cancer patients with diagnosis of solid tumours and who have not yet initiated Ayurveda therapy, completed a baseline survey indicating their primary expectations from the Ayurveda Rasayana Therapy. Results: The cohort was balanced for gender (1685 males,1666 females) with a mean age of 61.2 (±14.3) years. The most common cancers were breast (17.87%), colon (10.50%) and oral (10.08%) cancers with 60.6% of patients were of stage IV (advanced stage) and rest were of stage I-III. While 75.38% of patients (n = 2536) were of the opinion that cure is practically not possible in majority of cancers and long-term remission is better achievable option, 22% (n = 760) expected a cure, a proportion which does not differ between early and advanced stage (p > 0.05). Key objectives for seeking Ayurveda were, improvement in Quality of life (51% n = 1728), to get rid of adverse reactions of conventional anticancer therapies (31% n = 1050), dissatisfaction with prior medical treatment (27.24% n = 916) and to get maximum disease-free survival in the remission period /post-surgery (7.5% n = 678). Notably, 31% of the patients were incorrect when asked about their current stage of disease. Conclusions: Indian cancer patients approach ayurveda primarily to improve quality of life, manage treatment toxicity and enhance the disease-free survival highlighting critical unmet needs. However, a significant proportion of patients harbours unrealistic expectations and lack correct knowledge about their stage of disease, which can have an impact on their expectations. These findings underscore the urgent need for structured patient education and intensive research in the identified area of unmet medical needs so as to enhance a more efficient evidence-based model of integration. Also, patient education can ensure that patients expectations are aligned with evidence-based outcomes, ultimately leading to efficient and comprehensive cancer care.
Portable, real-time 3D ultrasound for operator-independent breast imaging
Atomic-Scale Selective C–H Halogenation Driven by Tip Electric Field in Water
A unified post-quantum zero-trust architecture with AI-driven orchestration for secure healthcare fog networks
FDA approves first-in-class hypertension drug
A Dual‐Bioresponsive and Programmable Microneedle Matrix as a Bioinspired Coupler for Orchestrating Diabetic Bone Regeneration
ABSTRACT Diabetic bone repair is impaired by a microenvironment characterized by heightened susceptibility to infection and persistent inflammation. This study presents a dissolvable, dual‐responsive (to glutathione and gelatinase) microneedle patch (CGF/PP@MN) for spatiotemporally controlled therapy. The system features a GelMA hydrogel matrix encapsulating Concentrated Growth Factors (CGF) within its core, while its surface is functionalized with a glutathione‐reactive anti‐inflammatory peptide (pro‐AIP) and a gelatinase‐cleavable antimicrobial peptide (pro‐AMP). This spatial design enables a sequential, pathology‐triggered release cascade: upon insertion, pro‐AMPs are first cleaved in the presence of bacterial gelatinase to eradicate biofilms; subsequently, the elevated glutathione concentration activates pro‐AIPs to mitigate inflammation and promote M2 macrophage polarization, thereby remodeling the hostile immune niche. Finally, the sustained release of CGF from the hydrogel core drives vascularization and osteogenesis. This platform demonstrates precise temporal alignment with endogenous healing, excellent biocompatibility, and robust bioactivity in vitro. In a diabetic bone defect model, it significantly enhanced wound healing, attenuated inflammation, promoted robust bone regeneration, and improved overall repair outcomes. This work provides a novel combinatorial strategy for immunomodulation and regenerative repair of diabetic bone defects.
A Metallic Element‐Free Halide‐Ion Battery Enabled by Dual‐halide Regulation in a Hydrogel Electrolyte
ABSTRACT Reducing the reliance on metal minerals in rechargeable batteries is an important step toward sustainable energy storage. Although aqueous halogen redox systems are attractive due to their high redox potentials and intrinsic safety, most reported configurations still depend on concentrated metal salt electrolytes and/or metal anodes, limiting their sustainability. Here, we develop a completely metallic element‐free halide‐ion aqueous battery composed of a reduced graphene oxide (rGO) cathode, a viologen‐based organic anode (TF‐Cl), and a dual‐halide hydrogel electrolyte. Incorporation of bromide and chloride species with distinct quaternary ammonium cations into a xanthan gum matrix establishes a confined ionic environment that stabilizes reactive polyhalide intermediates and suppresses shuttle behavior. Bromide–chloride interactions further regulate chlorine redox pathways, enabling cooperative stepwise halogen reactions with improved reversibility. Mechanistic studies indicate stabilized polyhalide formation and intercalation at the rGO cathode, together with reversible chloride storage at nitrogen redox sites in TF‐Cl. The assembled full battery exhibits a stable discharge plateau, good rate capability, and cycling stability over 2000 cycles, demonstrating competitive capacity and enhanced output voltage relative to representative aqueous systems with metal‐free electrodes.
A high-sensitivity strategy to screen NAD(P)H-dependent reductase activity by coupled enzyme cascade
Real-world efficacy and safety of first-line durvalumab combined with platinum–etoposide in extensive-stage small cell lung cancer: A single-center experience in Vietnam.
281 Background: Durvalumab combined with platinum–etoposide is the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) based on the CASPIAN trial. Real-world data in Southeast Asia remain limited. We evaluated the effectiveness and safety of this regimen in routine clinical practice in Vietnam. Methods: This single-center retrospective study included patients ≥18 years with histologically confirmed ES-SCLC and ECOG 0–1 treated with first-line etoposide–platinum plus durvalumab between July 2023 and August 2025. Treatment consisted of etoposide plus carboplatin or cisplatin with durvalumab (1500 mg every 3 weeks for 4 cycles), followed by maintenance durvalumab every 4 weeks until progression or unacceptable toxicity. Tumor response was assessed per RECIST v1.1. Survival was estimated using the Kaplan–Meier method. Adverse events were graded per CTCAE v5.0. Results: Forty patients were included. Median age was 63 years (range, 29–78); all were male and 95% were smokers. Carboplatin was used in 35/40 patients (87.5%). Liver metastases were present in 15% and brain metastases in 10%. The objective response rate was 67.5%, and disease control rate was 80%. At a median follow-up of 12.5 months, median progression-free survival was 7.0 months (95% CI, 5.5–11.7) and median overall survival was 13.5 months (95% CI, 10.9–NR). One- and two-year OS rates were 57.5% and 31%, respectively. No significant differences in OS were observed according to age, ECOG performance status, or number of metastatic sites. Grade 3 hematologic toxicities were infrequent, and immune-related adverse events were manageable, with no grade 4 events observed. Conclusions: In this real-world cohort, first-line etoposide–platinum plus durvalumab demonstrated encouraging survival outcomes and an acceptable safety profile in patients with ES-SCLC, consistent with pivotal trial data and supporting its feasibility in routine practice in Vietnam. Comparison of efficacy outcomes between CASPIAN and the current study. Study N ORR (%) mPFS (mo) mOS (mo) OS 2y (%) CASPIAN (2020) 268 68 5.1 12.9 22.9 Current study (2026) 40 67.5 7.0 13.5 31 Abbreviations: N, number of patients; ORR, objective response rate; mPFS, median progression-free survival; mOS, median overall survival; OS, overall survival; 2y, 2-year.
Genomic profiling of adolescent and young adult cancers in Asia: A scoping review.
166 Background: Adolescents and young adults (AYAs, aged 15–39 years) represent a distinct yet under-recognised cancer population, with survival outcomes that lag behind those of paediatric and older adult patients across many cancer types. Despite this, treatment strategies for AYAs are frequently extrapolated from other age groups rather than informed by age-specific evidence. In Asia, genomic data on AYA cancers remain particularly limited. This scoping review maps existing genomic profiling studies; to characterise the current evidence base and highlight gaps relevant to advancing precision oncology for Asian AYA patients. Methods: We conducted a scoping review following JBI methodology and PRISMA-ScR guidelines over three databases (PubMed, Embase, Scopus). Studies involving Asian AYAs undergoing multi-gene genomic profiling were included. Two reviewers independently screened titles, abstracts, and full texts, with data extracted using standardised forms. Results: We identified 14 studies published from 2006-2025, most within the past decade. More than half of the identified studies were conducted in East Asia (e.g. China, Japan). Colorectal and breast cancers predominated, while other cancer types prevalent among AYAs were strongly underrepresented. Across tumour types, AYAs exhibited distinct genomic features compared with older adults. These included differences in driver mutations, lower tumour mutational burden and higher rates of pathogenic germline variants. While most studies identified actionable mutations, only two studies utilised genomic findings in guiding eventual therapy. Conclusions: While emerging evidence indicates that Asian AYA cancers are characterised by age- and population-specific genomic patterns, its translation into clinical practice remains limited. Substantial regional inequities in sequencing access and research capacity further constrain implementation, particularly in under-resourced settings. Improved evidence synthesis will depend on harmonised AYA definitions and wider implementation of validated frameworks to evaluate and tier actionable alterations. Beyond methodology, an important paradigm shift is needed: recognising the unique tumour biology of AYAs and incorporating this explicitly into clinical data stratification and interpretation. Generating clinically meaningful, outcome-linked genomic evidence will also require deliberate efforts to improve AYA inclusion in clinical trials, enabling genomics-guided approaches to be evaluated and implemented across diverse Asian settings.
Adjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a phase IIA open-label pilot clinical trial
Abstract Drug-resistant tuberculosis remains a major global health challenge, and excessive inflammation may contribute to tissue damage and poor outcomes. We conducted a phase IIA prospective open-label pilot trial (ClinicalTrials.gov: NCT02781909) evaluating adjunctive ibuprofen in adults with pulmonary pre-extensively drug-resistant (pre-XDR) or extensively drug-resistant (XDR) tuberculosis in Georgia. Twenty-eight participants received individualized background anti-tuberculosis regimens alone ( n = 14) or with ibuprofen 400 mg daily for 2 months ( n = 14) and were followed for 6 months. The primary efficacy outcome was the proportion of participants showing clinical and/or microbiological benefit, assessed by sputum culture conversion, radiological evolution, and WHO-defined treatment outcomes. Secondary outcomes were safety and tolerability, health-related quality of life, and inflammatory and transcriptomic responses. Adding adjunctive ibuprofen did not improve month-2 sputum culture negativity, time to stable culture conversion, radiological evolution, or final treatment outcomes. Safety and tolerability were similar between groups. Adverse events were recorded and reviewed, but not formally graded for severity. Ibuprofen treatment was associated with numerically greater reductions in several blood-based inflammatory measures and in transcriptomic signature scores associated with poor tuberculosis outcomes. These findings are exploratory and do not demonstrate clinical benefit but indicate biological activity and support evaluation of anti-inflammatory host-directed therapies in larger controlled trials.